[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Natera Inc (NTRA)

Natera Inc (NTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,296,764
  • Shares Outstanding, K 143,215
  • Annual Sales, $ 2,306 M
  • Annual Income, $ -208,160 K
  • EBIT $ -317 M
  • EBITDA $ -273 M
  • 60-Month Beta 1.51
  • Price/Sales 17.47
  • Price/Cash Flow N/A
  • Price/Book 22.56

Options Overview Details

View History
  • Implied Volatility 62.08% (-0.51%)
  • Historical Volatility 46.62%
  • IV Percentile 87%
  • IV Rank 65.68%
  • IV High 76.67% on 04/23/26
  • IV Low 34.14% on 08/19/25
  • Expected Move (DTE 7) 14.62 (5.19%)
  • Put/Call Vol Ratio 0.95
  • Today's Volume 1,426
  • Volume Avg (30-Day) 1,602
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 32,655
  • Open Int (30-Day) 31,067
  • Expected Range 267.23 to 296.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 4
  • High Estimate $-0.36
  • Low Estimate $-0.59
  • Prior Year $-0.74
  • Growth Rate Est. (year over year) +36.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
208.79 +34.99%
on 06/12/26
288.04 -2.15%
on 07/06/26
+59.03 (+26.49%)
since 06/09/26
3-Month
184.00 +53.18%
on 04/10/26
288.04 -2.15%
on 07/06/26
+78.85 (+38.84%)
since 04/09/26
52-Week
131.81 +113.83%
on 08/01/25
288.04 -2.15%
on 07/06/26
+120.10 (+74.25%)
since 07/09/25

Most Recent Stories

More News
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off

1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off

NTRA : 281.85 (+2.72%)
IEX : 219.74 (+0.62%)
DPZ : 300.88 (-0.49%)
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU

NTRA : 281.85 (+2.72%)
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer

Newly published study shows Signatera MRD-positive patients lived longer with adjuvant chemotherapy, while MRD-negative patients saw no significant benefit First predictive...

NTRA : 281.85 (+2.72%)
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settings

NTRA : 281.85 (+2.72%)
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late...

NTRA : 281.85 (+2.72%)
ELDN : 4.13 (-1.90%)
Why Natera (NTRA) Stock Is Up Today

Why Natera (NTRA) Stock Is Up Today

NTRA : 281.85 (+2.72%)
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending final reimbursement...

NTRA : 281.85 (+2.72%)
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending...

NTRA : 281.85 (+2.72%)
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC) Marks third NCCN guideline recommendation on ctDNA-MRD testing, following...

NTRA : 281.85 (+2.72%)
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs

NTRA : 281.85 (+2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

3rd Resistance Point 296.84
2nd Resistance Point 290.30
1st Resistance Point 286.08
Last Price 281.85
1st Support Level 275.31
2nd Support Level 268.77
3rd Support Level 264.55

See More

52-Week High 288.04
Last Price 281.85
Fibonacci 61.8% 228.36
Fibonacci 50% 209.93
Fibonacci 38.2% 191.49
52-Week Low 131.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.